0001599298-22-000005.txt : 20220105 0001599298-22-000005.hdr.sgml : 20220105 20220105160145 ACCESSION NUMBER: 0001599298-22-000005 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220103 FILED AS OF DATE: 20220105 DATE AS OF CHANGE: 20220105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Clark Kenneth A CENTRAL INDEX KEY: 0001561736 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36866 FILM NUMBER: 22511040 MAIL ADDRESS: STREET 1: C/O PHARMACYCLICS, INC. STREET 2: 995 EAST ARQUES AVE. CITY: SUNNYVALE STATE: CA ZIP: 94085 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Summit Therapeutics Inc. CENTRAL INDEX KEY: 0001599298 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE BROADWAY STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-514-7149 MAIL ADDRESS: STREET 1: ONE BROADWAY STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Summit Therapeutics plc DATE OF NAME CHANGE: 20150219 FORMER COMPANY: FORMER CONFORMED NAME: Summit Corp plc DATE OF NAME CHANGE: 20140205 4 1 wf-form4_164141648612518.xml FORM 4 X0306 4 2022-01-03 0 0001599298 Summit Therapeutics Inc. SMMT 0001561736 Clark Kenneth A C/O SUMMIT THERAPEUTICS INC. ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 1 0 0 0 Stock Option (right to buy) 2.82 2022-01-03 4 A 0 25000 A 2032-01-03 Common Stock 25000.0 25000 D Stock Option (right to buy) 2.82 2022-01-03 4 A 0 58510 1.13 A 2032-01-03 Common Stock 58510.0 83510 D The option was granted on January 3, 2022. The shares underlying the option are scheduled to vest in equal quarterly installments, on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Not applicable. The option was issued on January 3, 2022. The shares underlying the option are scheduled to vest in four equal quarterly installments, on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $66,000. /s/ Kenneth A. Clark 2022-01-05